Decipher检测在前列腺癌主动监测候选者中预测不良病理的验证
该研究在前列腺癌主动监测(AS)候选者中验证Decipher检测预测不良病理(AP)的价值。研究先在前列腺切除标本中评估Decipher与生物学特征的相关性,随后在266例NCCN极低/低及有利中危患者的诊断活检中评估。结果显示Decipher是AP的独立预测因子,调整CAPRA后OR为1.29(每增加10%,95%CI 1.03-1.61,P=0.025),联合CAPRA将AUC从0.57提升至0.65。结论认为Decipher可用于活检预测无不良病理特征,辅助筛选AS合适患者。
要点
- Decipher是NCCN极低/低及有利中危前列腺癌患者不良病理的独立预测因子。
- Decipher联合CAPRA可提高对不良病理的预测能力(AUC从0.57升至0.65)。
- Decipher高阴性预测值(阈值0.45时91%,阈值0.2时96%)有助于确认无不良病理。
核心结论
- Decipher可应用于NCCN极低/低及有利中危风险患者的活检组织,预测无不良病理特征,这些患者是主动监测的良好候选者。
研究设计与样本
- 研究先在前瞻性前列腺切除队列中评估Decipher与临床有意义生物学特征的相关性,再在266例NCCN极低/低及有利中危风险前列腺癌患者的回顾性多中心诊断活检队列中评估Decipher。
主要发现
- 前列腺切除标本中Decipher与不良病理特征显著相关(p值<0.001)。
- 266例诊断活检中(64.7% NCCN极低/低危,35.3%有利中危),调整CAPRA后Decipher是不良病理的独立预测因子(每增加10%的OR为1.29,95%CI 1.03-1.61,p=0.025)。
- CAPRA的AUC为0.57(95%CI 0.47-0.68),加入Decipher后AUC提高至0.65(95%CI 0.58-0.70)。
- Decipher阈值0.45和0.2的阴性预测值分别为91%(95%CI 87-94%)和96%(95%CI 90-99%)。
- 使用阈值0.2时,调整CAPRA后Decipher仍是不良病理的显著预测因子(p=0.016)。
关键数值与推荐
- 不良病理定义:主要模式4或5、晚期局部分期(pT3b或更高)或淋巴结受累。
- Decipher每增加10%的OR为1.29(95%CI 1.03-1.61,p=0.025)。
- CAPRA的AUC为0.57(95%CI 0.47-0.68),联合Decipher后AUC为0.65(95%CI 0.58-0.70)。
- Decipher阈值0.45的阴性预测值为91%(95%CI 87-94%),阈值0.2的阴性预测值为96%(95%CI 90-99%)。
临床怎么用
- 对于NCCN极低/低及有利中危风险的前列腺癌患者,可考虑在诊断活检时使用Decipher检测辅助风险分层。
- Decipher高阴性预测值有助于识别无不良病理特征的患者,支持其成为主动监测的合适候选者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTACT: BACKGROUND: Many men diagnosed with prostate cancer are active surveillance (AS) candidates. However, AS may be associated with increased risk of disease progression and metastasis due to delayed therapy. Genomic classifiers, e.g., Decipher, may allow better risk-stratify newly diagnosed prostate cancers for AS. METHODS: Decipher was initially assessed in a prospective cohort of prostatectomies to explore the correlation with clinically meaningful biologic characteristics and then assessed in diagnostic biopsies from a retrospective multicenter cohort of 266 men with National Comprehensive Cancer Network (NCCN) very low/low and favorable-intermediate risk prostate cancer. Decipher and Cancer of the Prostate Risk Assessment (CAPRA) were compared as predictors of adverse pathology (AP) for which there is universal agreement that patients with long life-expectancy are not suitable candidates for AS (primary pattern 4 or 5, advanced local stage [pT3b or greater] or lymph node involvement). RESULTS: Decipher from prostatectomies was significantly associated with adverse pathologic features (p-values < 0.001). Decipher from the 266 diagnostic biopsies (64.7% NCCN-very-low/low and 35.3% favorable-intermediate) was an independent predictor of AP (odds ratio 1.29 per 10% increase, 95% confidence interval [CI] 1.03-1.61, p-value 0.025) when adjusting for CAPRA. CAPRA area under curve (AUC) was 0.57, (95% CI 0.47-0.68). Adding Decipher to CAPRA increased the AUC to 0.65 (95% CI 0.58-0.70). NPV, which determines the degree of confidence in the absence of AP for patients, was 91% (95% CI 87-94%) and 96% (95% CI 90-99%) for Decipher thresholds of 0.45 and 0.2, respectively. Using a threshold of 0.2, Decipher was a significant predictor of AP when adjusting for CAPRA (p-value 0.016). CONCLUSION: Decipher can be applied to prostate biopsies from NCCN-very-low/low and favorable-intermediate risk patients to predict absence of adverse pathologic features. These patients are predicted to be good candidates for active surveillance.
引用
- Kim HL, Li P, Huang HC, et al. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2018. PMID: 30542054. doi:10.1038/s41391-018-0101-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。